Payment overview · 2025
General Payments
$335.74
14 reported records · 6 companies
Healthcare provider profile · identity verified
Gagandeep Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HARTFORD, CT · NPI 1003055021
Verified facts
What the public records show
CMS Open Payments records show Gagandeep Singh, MD received $335.74 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 49.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ingrezza, Xifaxan.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 979 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $166.70 | 49.6% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $73.38 | 21.9% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.60 | 10.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.43 | 6.4% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.81 | 6.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $16.82 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $335.74 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $117.67 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $117.67 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $95.59 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $73.38 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $49.03 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 979 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
979 | 114 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1481 | 224 |
| Eliquis | Apixaban | 979 | 114 |
| Trazodone Hcl | Trazodone Hcl | 901 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 765 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 637 | 88 |
| Gabapentin | Gabapentin | 611 | 106 |
| Furosemide | Furosemide | 593 | 86 |
| Omeprazole | Omeprazole | 564 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 517 | 77 |
| Lisinopril | Lisinopril | 478 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 410 | 62 |
| Sertraline Hcl | Sertraline Hcl | 406 | 59 |
| Metformin Hcl | Metformin Hcl | 387 | 53 |
| Mirtazapine | Mirtazapine | 379 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 84 |
| Risperidone | Risperidone | 336 | 36 |
| Losartan Potassium | Losartan Potassium | 321 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 307 | 60 |
| Potassium Chloride | Potassium Chloride | 297 | 50 |
| Divalproex Sodium | Divalproex Sodium | 285 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 259 | 44 |
| Clozapine | Clozapine | 257 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 250 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 249 | 37 |
| Tradjenta | Linagliptin | 224 | 13 |
| Levetiracetam | Levetiracetam | 216 | 29 |
| Olanzapine | Olanzapine | 206 | 31 |
| Aripiprazole | Aripiprazole | 198 | 24 |
| Famotidine | Famotidine | 190 | 31 |
| Januvia | Sitagliptin Phosphate | 188 | 22 |
| Lamotrigine | Lamotrigine | 186 | 11 |
| Torsemide | Torsemide | 184 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 174 | 14 |
| Xarelto | Rivaroxaban | 171 | 20 |
| Warfarin Sodium | Warfarin Sodium | 165 | suppressed |
| Prednisone | Prednisone | 154 | 62 |
| Allopurinol | Allopurinol | 152 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 152 | 19 |
| Carvedilol | Carvedilol | 150 | 30 |
| Donepezil Hcl | Donepezil Hcl | 145 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 12 |
| Buspirone Hcl | Buspirone Hcl | 134 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 20 |
| Jardiance | Empagliflozin | 128 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 127 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 14 |
| Finasteride | Finasteride | 120 | 21 |
| Enulose | Lactulose | 117 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 114 | 18 |
| Atropine Sulfate | Atropine Sulfate | 107 | 19 |
| Haloperidol | Haloperidol | 106 | suppressed |
| Lactulose | Lactulose | 106 | 24 |
| Latanoprost | Latanoprost | 104 | 25 |
| Lurasidone Hcl | Lurasidone Hcl | 104 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 102 | 27 |
| Baclofen | Baclofen | 100 | 19 |
| Myrbetriq | Mirabegron | 97 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 41 |
| Simvastatin | Simvastatin | 91 | 15 |
| Oxcarbazepine | Oxcarbazepine | 90 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 90 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 12 |
| Memantine Hcl | Memantine Hcl | 85 | 15 |
| Midodrine Hcl | Midodrine Hcl | 84 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 18 |
| Spironolactone | Spironolactone | 83 | 22 |
| Trintellix | Vortioxetine Hydrobromide | 79 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 78 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 14 |
| Digoxin | Digoxin | 75 | 11 |
| Montelukast Sodium | Montelukast Sodium | 74 | 18 |
| Haloperidol Lactate | Haloperidol Lactate | 72 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 16 |
| Alendronate Sodium | Alendronate Sodium | 70 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 64 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 63 | suppressed |
| Methocarbamol | Methocarbamol | 61 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 56 | 27 |
| Humalog | Insulin Lispro | 55 | 18 |
| Metformin Hcl Er | Metformin Hcl | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 50 | 25 |
| Ibuprofen | Ibuprofen | 49 | 12 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 31 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 45 | 36 |
| Ezetimibe | Ezetimibe | 45 | 11 |
| Linzess | Linaclotide | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Tirosint-Sol | Levothyroxine Sodium | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 41 | 33 |
| Cefuroxime | Cefuroxime Axetil | 40 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 16 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 24 |
| Sucralfate | Sucralfate | 40 | suppressed |
| Austedo | Deutetrabenazine | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 39 | 15 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 39 | suppressed |
| Olanzapine Odt | Olanzapine | 39 | suppressed |
| Paliperidone Er | Paliperidone | 39 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 39 | suppressed |
| Budesonide | Budesonide | 38 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | 14 |
| Fluconazole | Fluconazole | 38 | suppressed |
| Kerendia | Finerenone | 38 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 24 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Restasis | Cyclosporine | 36 | suppressed |
| Ingrezza | Valbenazine Tosylate | 35 | suppressed |
| Perphenazine | Perphenazine | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 33 | suppressed |
| Azithromycin | Azithromycin | 31 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 29 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 28 | 18 |
| Roflumilast | Roflumilast | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 25 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | 13 |
| Rhopressa | Netarsudil Mesylate | 25 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Mupirocin | Mupirocin | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Dupixent Syringe | Dupilumab | 18 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | 13 |
| Ozempic | Semaglutide | 18 | suppressed |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | 12 |
| Metronidazole | Metronidazole | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Ramelteon | Ramelteon | 16 | suppressed |
| Acetic Acid | Acetic Acid | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 13 |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Liraglutide | Liraglutide | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.74 · 14 records | PFIZER INC. | ELIQUIS, INGREZZA, LifeVest, NURTEC ODT, PAXLOVID, ULTOMIRIS, VYNDAQEL, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error